Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis

Justine Deroissart  1 , Florentina Porsch  1 , Thomas Koller  1 , Christoph J. Binder  1
Arnold von Eckardstein  1 , Christoph J. Binder  2
, editors.
In: Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022.
.
Affiliations
Free Books & Documents
Review

Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis

Justine Deroissart et al.
Free Books & Documents

Excerpt

Hypercholesterolemia is a major risk factor in atherosclerosis development and lipid-lowering drugs (i.e., statins) remain the treatment of choice. Despite effective reduction of LDL cholesterol in patients, a residual cardiovascular risk persists in some individuals, highlighting the need for further therapeutic intervention. Recently, the CANTOS trial paved the way toward the development of specific therapies targeting inflammation, a key feature in atherosclerosis progression. The pre-existence of multiple drugs modulating both innate and adaptive immune responses has significantly accelerated the number of translational studies applying these drugs to atherosclerosis. Additional preclinical research has led to the discovery of new therapeutic targets, offering promising perspectives for the treatment and prevention of atherosclerosis. Currently, both drugs with selective targeting and broad unspecific anti-inflammatory effects have been tested. In this chapter, we aim to give an overview of current advances in immunomodulatory treatment approaches for atherosclerotic cardiovascular diseases.

PubMed Disclaimer

References

    1. Abbate A, Kontos MC, Grizzard JD et al (2010) Interleukin-1 blockade with Anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra remodeling trial [VCU-ART] pilot study). AJC 105:1371–1377. https://doi.org/10.1016/j.amjcard.2009.12.059 - DOI - PubMed
    1. Abbate A, Van Tassell BW, Biondi-Zoccai G et al (2013) Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia commonwealth university-anakinra remodeling trial (2) (vcu-art 2) pilot study]. Am J Cardiol 111:1394–1400. https://doi.org/10.1016/j.amjcard.2013.01.287 - DOI - PMC - PubMed
    1. Abbate A, Trankle CR, Buckley LF et al (2020) Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc 9:e014941. https://doi.org/10.1161/JAHA.119.014941 - DOI - PMC - PubMed
    1. Ait-Oufella H, Salomon BL, Potteaux S et al (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12:178–180. https://doi.org/10.1038/nm1343 - DOI - PubMed
    1. Ait-Oufella H, Herbin O, Bouaziz J-D et al (2010) B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 207:1579–1587. https://doi.org/10.1084/jem.20100155 - DOI - PMC - PubMed

LinkOut - more resources